Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2016 1
2017 3
2018 3
2019 6
2020 9
2021 12
2022 5
2023 13
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

44 results

Results by year

Filters applied: . Clear all
Page 1
Integrating [18F]-Fluorodeoxyglucose Positron Emission Tomography with Computed Tomography with Radiation Therapy and Immunomodulation in Precision Therapy for Solid Tumors.
Prendergast CM, Lopci E, Seban RD, De Jong D, Ammari S, Aneja S, Lévy A, Sajan A, Salvatore MM, Cappacione KM, Schwartz LH, Deutsch E, Dercle L. Prendergast CM, et al. Among authors: seban rd. Cancers (Basel). 2023 Oct 27;15(21):5179. doi: 10.3390/cancers15215179. Cancers (Basel). 2023. PMID: 37958353 Free PMC article.
A common [18F]-FDG PET radiomic signature to predict survival in patients with HPV-induced cancers.
Niyoteka S, Seban RD, Rouhi R, Scarsbrook A, Genestie C, Classe M, Carré A, Sun R, La Greca Saint-Esteven A, Chargari C, McKenna J, McDermott G, Malinen E, Tanadini-Lang S, Guckenberger M, Guren MG, Lemanski C, Deutsch E, Robert C. Niyoteka S, et al. Among authors: seban rd. Eur J Nucl Med Mol Imaging. 2023 Nov;50(13):4010-4023. doi: 10.1007/s00259-023-06320-2. Epub 2023 Aug 26. Eur J Nucl Med Mol Imaging. 2023. PMID: 37632562
[18F]FDG PET/CT for predicting triple-negative breast cancer outcomes after neoadjuvant chemotherapy with or without pembrolizumab.
Seban RD, Arnaud E, Loirat D, Cabel L, Cottu P, Djerroudi L, Hescot S, Loap P, Bonneau C, Bidard FC, Huchet V, Jehanno N, Berenbaum A, Champion L, Buvat I. Seban RD, et al. Eur J Nucl Med Mol Imaging. 2023 Nov;50(13):4024-4035. doi: 10.1007/s00259-023-06394-y. Epub 2023 Aug 22. Eur J Nucl Med Mol Imaging. 2023. PMID: 37606858
PET/CT and SPECT/CT Imaging of HER2-Positive Breast Cancer.
McGale J, Khurana S, Huang A, Roa T, Yeh R, Shirini D, Doshi P, Nakhla A, Bebawy M, Khalil D, Lotfalla A, Higgins H, Gulati A, Girard A, Bidard FC, Champion L, Duong P, Dercle L, Seban RD. McGale J, et al. Among authors: seban rd. J Clin Med. 2023 Jul 25;12(15):4882. doi: 10.3390/jcm12154882. J Clin Med. 2023. PMID: 37568284 Free PMC article. Review.
Advances in PET/CT Imaging for Breast Cancer.
de Jong D, Desperito E, Al Feghali KA, Dercle L, Seban RD, Das JP, Ma H, Sajan A, Braumuller B, Prendergast C, Liou C, Deng A, Roa T, Yeh R, Girard A, Salvatore MM, Capaccione KM. de Jong D, et al. Among authors: seban rd. J Clin Med. 2023 Jul 7;12(13):4537. doi: 10.3390/jcm12134537. J Clin Med. 2023. PMID: 37445572 Free PMC article. Review.
Total Metabolic Tumor Volume on 18F-FDG PET/CT Is a Useful Prognostic Biomarker for Patients with Extensive Small-Cell Lung Cancer Undergoing First-Line Chemo-Immunotherapy.
Grambow-Velilla J, Seban RD, Chouahnia K, Assié JB, Champion L, Girard N, Bonardel G, Matton L, Soussan M, Chouaïd C, Duchemann B. Grambow-Velilla J, et al. Among authors: seban rd. Cancers (Basel). 2023 Apr 10;15(8):2223. doi: 10.3390/cancers15082223. Cancers (Basel). 2023. PMID: 37190152 Free PMC article.
44 results